Uriel Pharmacy's homeopathic ampule drugs are unapproved new drugs and were made under serious CGMP violations.
What happened
FDA inspected Uriel Pharmacy's East Troy, WI drug manufacturing facility from February 25 to March 4, 2025, and found significant CGMP violations, including inadequate in-process and finished-product testing, component identity testing, laboratory controls, and quality-unit oversight. FDA also reviewed labeling collected during the inspection and on www.shopuriel.com and found the homeopathic ampule drug products are unapproved new drugs. FDA said the glass ampules could be mistaken for injectable drugs, posing a risk of serious harm if injected.
What FDA found
Uriel failed to establish and follow adequate controls to monitor and validate manufacturing processes and failed to perform appropriate finished-product laboratory testing for identity and strength before release.
21 CFR 211.110(a); 21 CFR 211.165(a)Uriel failed to test each component lot for identity and conformity with written specifications, including purchased water and glycerin, and did not verify supplier certificates of analysis.
21 CFR 211.84(d)(1) and (2)Uriel failed to establish scientifically sound laboratory controls, including validated alternative microbiological methods, adequate microbial limits, testing for Burkholderia cepacia, and antimicrobial effectiveness testing.
21 CFR 211.160(b)Uriel's quality unit did not effectively exercise authority to approve or reject materials and products or oversee quality, and the firm lacked adequate change control, annual production review, adverse event reporting, and batch records.
21 CFR 211.22(a); 21 CFR 211.125(a); 21 CFR 211.180(e); 21 CFR 211.198(a); 21 CFR 211.188(b)Uriel's homeopathic ampule drugs are unapproved new drugs sold without FDA-approved applications, based on labeling claims such as temporary relief of digestive upset, headache, flu symptoms, upset stomach, and broken bone healing.
FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)Uriel's aseptic processing and cleaning practices for drugs in glass ampules were inadequate for sterile injectable drugs, including use of non-sterile cleaning agents and inadequate contact times.
21 CFR 211.113(b)
What FDA wants
FDA asks Uriel to provide comprehensive assessments, test results, and corrective action plans in response to the letter, including DEG and EG test results no later than 30 calendar days from the letter date. FDA also asks for prompt actions such as customer notification or recalls if testing finds contaminated or substandard product.
Who should pay attention
- clinics and pharmacies that stock or dispense homeopathic ampules
- companies that buy Uriel-made drugs or rely on it as a contract manufacturer
- suppliers and distributors of glycerin and pharmaceutical water
This is a summary. Read the original letter on fda.gov.